Osteoporosis

Systemic Mastocytosis

Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections

Denosumab

Placebo

Jean Minjoz Hospital, Dermatology department

Caen Hospital, Clinical haematology department

Estaing Hospital, Cellular therapy and clinical haematology department

Lille CHRU Hospital, Internal medicine and clinical immunology department

La Timone Hospital, Dermatology and cutaneous oncology department

Lapeyronie Hospital, Rheumatology and Immunology department

La Pitié-Salpêtrière Hospital, Internal medicine and clinical immunology department

Cochin Hospital, Rheumatology department

Necker Hospital, Adult haematology department

Strasbourg Hospital, Rheumatology department

Toulouse Hospital, Dermatology department

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

Dual energy x-ray absorptiometry at lumbar spine (L2-L4)

Dual energy x-ray absorptiometry at left femoral neck and total left hip

Biological assessment: complete blood count, creatinemia, electrolytes, aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, c-reactive protein (CRP), phosphocalcic analyses with calcemia, phosphoremia, parathormone, vitamin D (25-OH-D), β-Human Chorionic Gonadotropin (HCG) (if needed)
Clinical assessment: blood pressure, pulse, weight, height, PS, temperature

Dual energy x-ray absorptiometry at lumbar spine (L2-L4), left femoral neck and total left hip

urticaria pigmentosa/tyrosine

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

Najkompletnija baza ljekovitog bilja potpomognuta znanošću